Search
for
Sort by
Research 121–150 of 121
- In Vitro and In Vivo Evaluation of Chitosan/HPMC/Insulin Hydrogel for Wound Healing Applications
- Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359
- Assessment of the Pharmacokinetic -Pharmacodynamic Interaction Between Terazosin and Finasteride
- Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359
- Terazosin or baclofen in young men with chronic orchialgia: A cohort study of 499 patients
- Terazosin reduced BPH symptoms and finasteride did not
- Anaphylactic shock associated with finasteride and terazosin
- Comparación del efecto terapéutico entre el extracto etanólico del fruto de Physalis peruviana, Finasteride y Terazosine en la hiperplasia prostática benigna inducida en ratas
- Validated HPTLC method for the simultaneous determination of alfuzosin, terazosin, prazosin, doxazosin and finasteride in pharmaceutical formulations
- Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin
- ALOPESİ AREATA OLGULARINDA SANAT TERAPİSİNİN KULLANILMASI: BİR OLGU SUNUMU
- Rapid and Sensitive LC–MS–MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma
- Risk factors for intraoperative floppy iris syndrome: a retrospective study
- A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
- Doxazosin and finasteride alone or in combination: the PREDICT study
- Is sulfonamide group of tamsulosin main factor in the pathophysiology of floppy iris syndrome?
- Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
- THE TREATMENT OF BPH WITH HYPERTENSION
- Key Clinical Trials in BPH
- Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study
- Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern Grundlagen und klinische Ergebnisse
- Direct Vasodilators and Sympatholytic Agents
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Risk factors for intraoperative floppy iris syndrome: One year prospective study
- Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
- The role of dutasteride in the treatment of benign prostatic obstruction and related conditions
- Treatment of Hair Loss